JAK Inhibitors and Endothelial Cardiovascular Risk

Cardiovascular risk in inflammatory disease cannot be inferred from cytokine suppression alone. The study by Zavoriti and Miossec, published in ACR Open Rheumatology, addresses this issue by comparing how different JAK inhibitors affect human endothelial cells exposed to a combined TNF and IL-17A inflammatory stimulus. The complete report is available through the reference study.

Study Background and Research Question

Patients with rheumatoid arthritis have a higher incidence of cardiovascular disease than the general population, in part because persistent systemic inflammation can disrupt vascular homeostasis. TNF and IL-17A are particularly relevant to this process. Together, they can increase endothelial release of IL-6 and IL-8, promote expression of VCAM-1, ICAM-1, and E-selectin, induce tissue factor, suppress thrombomodulin, and contribute to endothelial apoptosis. These changes favor leukocyte recruitment and a procoagulant vascular state.

The JAK-STAT signaling pathway regulates signals from several inflammatory cytokines, including IL-6, IL-23, and interferon-γ. TNF and IL-17A, however, do not directly signal through JAK-STAT. This distinction creates an important research question: if JAK inhibition reduces inflammatory mediator production in endothelial cells, does it also correct the adhesion and coagulation abnormalities induced by TNF plus IL-17A?

The investigators therefore asked whether approved JAK inhibitors produce similar or distinct effects on endothelial inflammation, adhesion-molecule expression, coagulation and fibrinolysis genes, and apoptosis. The question is directly relevant to inflammatory disorder research because clinical safety signals may reflect more than the ability of a drug to reduce circulating inflammatory markers.

Key Innovation from the Reference Study

The main innovation is the separation of several endothelial response layers within the same inflammatory model. Rather than treating reduced cytokine release as a complete indicator of vascular benefit, the study examined inflammatory secretion, leukocyte-adhesion programs, procoagulant signaling, anticoagulant loss, and cell survival in parallel.

This design revealed a central asymmetry. All tested JAK inhibitors reduced IL-6 release, but this common effect did not translate into a common improvement in endothelial adhesion or coagulation markers. In other words, pharmacological suppression of one inflammatory output was compatible with persistence, or even enhancement, of other vascular abnormalities. The comparison also identified drug-specific effects: some agents reduced IL-8, some altered adhesion molecules, and others produced cytotoxic or proapoptotic responses.

The result is more informative than a simple rank order of JAK inhibitors. It suggests that inhibitor selectivity, concentration, cellular context, and the inflammatory pathway being measured can all influence the observed vascular phenotype. The work consequently provides a mechanistic bridge between immune regulation research and endothelial biology without claiming that an in vitro response directly predicts clinical cardiovascular outcomes.

Methods and Experimental Design Insights

The investigators used human vascular endothelial cells and induced a strong inflammatory state with TNF plus IL-17A. The cells were treated with tofacitinib, baricitinib, upadacitinib, peficitinib, ruxolitinib, or fedratinib, or left untreated. Each inhibitor was evaluated at 1 or 10 μM in the reference study. This comparative panel included JAK inhibitors with different reported target preferences, allowing the authors to examine whether endothelial outcomes tracked simply with nominal JAK selectivity.

Protocol Parameters

• Inflammatory challenge: expose human vascular endothelial cells to combined TNF and IL-17A to model cytokine-driven endothelial dysfunction, following the conditions described in the reference study.
• Inhibitor comparison: evaluate tofacitinib, baricitinib, upadacitinib, peficitinib, ruxolitinib, and fedratinib under matched treatment conditions rather than comparing isolated compounds across separate experiments.
• Concentration design: the published experiment used 1 and 10 μM, enabling assessment of concentration-dependent divergence between anti-inflammatory and potentially adverse endothelial effects.
• Secreted mediators: quantify IL-6 and IL-8 in culture supernatants by enzyme-linked immunosorbent assay, as reported in the study methods.
• Vascular gene responses: use quantitative reverse transcriptase-polymerase chain reaction to measure adhesion molecules and factors associated with coagulation and fibrinolysis.
• Cell survival: assess endothelial apoptosis by Annexin V staining and interpret cytotoxicity separately from cytokine suppression.

This structure is useful for assay planning because it prevents a single readout from carrying too much interpretive weight. A compound that lowers IL-6 but increases VCAM-1 or ICAM-1 under the same condition should not be described as uniformly protective to the endothelium. Conversely, a change in gene expression should not automatically be treated as a demonstrated change in thrombosis unless it is supported by functional vascular assays.

Core Findings and Why They Matter

Shared suppression of IL-6, but not IL-8

All six JAK inhibitors reduced IL-6 release from endothelial cells stimulated with TNF plus IL-17A. The response was therefore shared across the panel and confirms that JAK inhibition can influence part of the inflammatory endothelial program even when the initiating cytokines do not directly signal through JAK-STAT.

IL-8 showed a more selective pattern. Only baricitinib and fedratinib reduced the cytokine-induced IL-8 overproduction at the lower concentration tested, 1 μM in the study. This difference demonstrates why measuring several cytokines is important: IL-6 and IL-8 cannot be assumed to provide interchangeable evidence of endothelial normalization.

Adhesion molecules showed drug- and concentration-dependent effects

Fedratinib reduced VCAM-1 and E-selectin induction at both tested concentrations. Tofacitinib reduced ICAM-1 and E-selectin induction at the lower concentration. However, at the higher concentration, tofacitinib, baricitinib, upadacitinib, peficitinib, and ruxolitinib enhanced the TNF-plus-IL-17A-induced expression of VCAM-1 and ICAM-1, according to the reference results.

This finding is particularly important for lymphocyte recruitment biology. Adhesion molecules regulate how circulating leukocytes interact with activated endothelium, so increased VCAM-1 or ICAM-1 may offset benefits suggested by lower soluble cytokine levels. It also highlights the need to treat concentration as an experimental variable rather than a minor technical detail.

Coagulation and anticoagulation responses were not uniformly corrected

Peficitinib and fedratinib reduced tissue-factor up-regulation at both concentrations, whereas ruxolitinib was effective only at the lower concentration. None of the tested inhibitors prevented the inflammation-associated down-regulation of thrombomodulin. Thus, the compounds could attenuate selected procoagulant signals without restoring the full anticoagulant phenotype.

The distinction matters because tissue factor induction and thrombomodulin loss represent different sides of vascular hemostatic regulation. A partial improvement in one pathway does not establish recovery of endothelial anticoagulant function. The findings support a multidimensional interpretation of vascular pharmacology rather than a single-marker safety model.

Apoptosis separated two inhibitors from the rest

Fedratinib and peficitinib showed proapoptotic and cytotoxic effects in the endothelial model. This observation adds a cell-survival dimension to the comparison. Endothelial apoptosis can aggravate barrier dysfunction and expose a more thrombogenic vascular surface, so an anti-inflammatory effect must be interpreted alongside viability data.

Overall, the study shows that all JAK inhibitors were not equivalent: some reduced selected inflammatory outputs, some modified adhesion or tissue-factor responses, and two produced evidence of endothelial toxicity under the tested conditions.

Comparison with Existing Internal Articles

The internal article Tofacitinib citrate: Reliable Assay Design approaches the topic from an operational perspective, emphasizing concentration selection, solvent controls, and interpretation of viability, proliferation, cytotoxicity, and inflammatory assays. It complements the reference study by translating the paper’s central lesson into workflow planning: cytokine suppression should be evaluated together with viability and endothelial phenotype.

Tofacitinib Citrate: From JAK3 to Vascular Insight provides a translational framing around JAK3-preferring immune modulation and vascular experiments. The current paper supplies the comparative evidence that such framing requires, showing that tofacitinib’s endothelial effects cannot be generalized to all JAK inhibitors or summarized by a single anti-inflammatory endpoint.

Why this cross-domain matters, maturity, and limitations

The study connects immune-pathway pharmacology with vascular risk biology. That connection is scientifically useful because drugs developed for inflammatory disease can influence endothelial responses indirectly through cytokine networks, even when the initiating cytokines are not direct JAK-STAT ligands. The evidence is mature enough to justify multidimensional in vitro screening, but it is not a clinical ranking of cardiovascular safety.

Several limitations constrain transferability. The experiments used cultured human endothelial cells and a deliberately intense TNF-plus-IL-17A challenge, which may not reproduce the temporal, cellular, and hemodynamic complexity of an intact vessel. The tested micromolar concentrations also require careful comparison with exposure levels relevant to a specific experimental system. Gene-expression changes and Annexin V staining provide valuable mechanistic signals, but they do not substitute for flow-dependent endothelial assays, platelet interactions, in vivo thrombosis models, or clinical outcome studies.

The model also cannot by itself establish which intracellular target accounts for each response. Because TNF and IL-17A do not directly activate JAK-STAT, the observed effects may involve pathway cross-talk, secondary cytokine signaling, or cell-state changes. These uncertainties reinforce the authors’ conclusion that JAK-inhibitor vascular effects are heterogeneous and context dependent.

Research Support Resources

Researchers can use Tofacitinib citrate (CP-690550 citrate) (SKU A4135) to support related endothelial, cytokine, and immune regulation research workflows. The product information describes a JAK3-preferring research compound and typical experimental use in the nanomolar range, whereas the reference paper tested tofacitinib at 1 and 10 μM; these ranges should not be treated as interchangeable. Appropriate solvent controls, concentration-response testing, endothelial viability measurements, and separate assessments of cytokine, adhesion, and coagulation endpoints remain essential for reproducible interpretation.